Wave Life Sciences

Company WVE

Last mentioned: Feb 26, 2026

Timeline

Invalid Date
Anticipated Filing

Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
Feb 26, 2026
FY 2025 Earnings

Wave and Collegium release full-year financial results and 2026 guidance.
Invalid Date
RNA Editing Milestone

WVE-006 demonstrates successful RNA editing in AATD patients.
Invalid Date
DMD Breakthrough

Wave reports industry-leading dystrophin expression for WVE-N531.

Stories mentioning Wave Life Sciences 1

Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs

Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.

Feb 26, 2026 2 sources